Skip to main content
. 2019 Jan 4;60(3):528–538. doi: 10.1194/jlr.M089722

Fig. 2.

Fig. 2.

Mogat1 ASO treatment suppresses fasting-induced Mogat1 expression and MGAT activity. Male C57BL/6J mice were injected (intraperitoneally) twice weekly with ASOs targeted against Mogat1 or scramble control (25 mg/kg) for 3 weeks prior to fasting (24 h) and liver harvest. A: Fasting mice receiving Mogat1 ASO had significantly lower Mogat1, but not Mogat2, gene expression during fasting compared with controls. B: Mogat1 ASO knockdown suppresses fasting-induced MGAT activity compared with controls. C: Fasting lowered eWAT expression of Mogat1, and Mogat1 was suppressed in both states by Mogat1 ASO treatments. D: eWAT MGAT activity was lowered by Mogat1 ASO treatment in the fed state. E: eWAT weight decreased with fasting in control-treated mice, but was not significantly changed by the ASO treatment. Data are shown as mean ± SE. *P < 0.05 where indicated; †P < 0.05 versus fed state; n = 4–5.